Active Surveillance

A Johns Hopkins study of more than 1,800 men ages 52 to 62 suggests that African-Americans diagnosed with very-low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.  Although prior studies have found it safe to delay treatment and monitor some presumably slow-growing or low-risk prostate cancers, such “active surveillance” (AS) does not appear to be a good idea for black men, the study concludes. Read the article.

Active surveillance (AS) may be an appropriate management option in carefully selected prostate cancer (PCa) patients with a baseline PSA level of 10 ng/mL or higher, according to study findings presented at the American Urological Association annual meeting. The study showed that these patients are no more likely to experience pathologic progression that patients with lower PSA levels at baseline. Read the article.

5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance Jill Stein Published Online: Monday, May 14, 2012 With reference to Antonio Finelli, MD, University Health Network, Princess Margaret Hospital Click here to view article.

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Interpretation Dutasteride could provide a beneficial adjunct to active surveillance for men with low-risk prostate cancer. Click here for full article.

Dr. Myers compares active surveillance and watchful waiting for prostate cancer in this 6:51 video. Click here to view.